PLEASANTON, Calif.,
Sept. 11, 2012 /PRNewswire/
-- Thoratec Corporation (NASDAQ: THOR), a world leader in
device-based mechanical circulatory support therapies to save,
support and restore failing hearts, said today it will be
participating in two upcoming investor conferences.
On Thursday, September 13, the
company will participate in the ThinkEquity 9th Annual
Growth Conference. Taylor C. Harris,
Senior Director of Investor Relations and Business Development,
will provide an update on the company beginning at 2:30 p.m., Eastern Daylight Time (11:30 a.m., Pacific Daylight Time). The
presentation will be available through the conference web site at
http://wsw.com/webcast/tep22/thor/, or on the company's web site at
http://www.thoratec.com.
On Wednesday, September 19,
Thoratec will participate in the UBS 2012 Global Life Sciences
Conference. The presentation by Taylor C.
Harris, Senior Director of Investor Relations and Business
Development, will begin at 8:30 a.m.,
Eastern Daylight Time (5:30 a.m.,
Pacific Daylight Time). The presentation will be available
through the conference web site at
http://cc.talkpoint.com/ubsx001/091912a_im/?entity=55_7YKIS01, or
on the company's web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company's products include the
HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD
(Ventricular Assist Device) with more than 20,000 devices implanted
in patients suffering from heart failure. Thoratec also
manufactures and distributes the CentriMag® and PediMag®/PediVAS®
product lines. Thoratec is headquartered in Pleasanton, California. For more information,
visit the company's web site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear
are registered trademarks of Thoratec Corporation. CentriMag and
PediMag are registered trademarks of Thoratec LLC, and PediVAS is a
registered trademark of Thoratec Switzerland GmbH.
SOURCE Thoratec Corporation